CooperVision Provides Translations to Boost Global Access
SAN RAMON, CALIF., July 10, 2023— As part of efforts to advance the acceptance of myopia control and management as standard of care, the newly published World Society of Paediatric Ophthalmology & Strabismus (WSPOS) Myopia Consensus Statement 2023 is now available in multiple languages. Translations in three languages were provided by CooperVision, a global category leader, and are available at wspos.org.
The statement, which is available in Portuguese, Spanish and French, concludes that there is “sufficient evidence to warrant the adoption of myopia prevention and control measures in clinical practice in children with progressive myopia.” Additional language translations including Arabic, Indonesian, Ukrainian, Hindi, Hungarian, Polish, Filipino, Romanian, Hindi, Telugu, Odia, Traditional Chinese, Simplified Chinese, and Japanese are to come.
“We recognize the significance of the WSPOS Myopia Consensus Statement to raise awareness and drive urgency for treating myopia among ophthalmologists. Translating these statements will help expand professional knowledge and treatment around the world,” said Elizabeth Lumb, BSc (Hons) MCOptom, FBCLA, Director of Global Professional Affairs, Myopia Management, CooperVision.
The WSPOS guidance is based on studies that have demonstrated both statistical and clinical significance in the effectiveness of slowing myopia progression, with all listed interventions having at least two years of peer-reviewed data. In referring to MiSight® 1 day, the authors share highlights from the landmark long-term, international MiSight® 1 day clinical trial to convey its efficacy, including children aged 8 to 12 showed a 59% reduction in rate of myopia progression over a 3-year period, compared to single vision contact lenses.1*
Lumb added, “In addition to its latest guidance, the WSPOS has begun an Independent Medical Educational series on myopia, made possible in part through a CooperVision grant. Past webinars are available on demand at forum.wspos.org/myopia-management. Through initiatives like these, CooperVision continues to find inventive ways to broaden access to the most recent and accurate evidence-based information available in the eye care industry.”
Now prescribed in more than 30 countries, MiSight® 1 day is the first and only soft contact lens approved* by the U.S. FDA and China NMPA to slow the progression of myopia in children aged 8-12 at the initiation of treatment.1 Building on the three-year data referenced in the WSPOS statement, peer-reviewed six-year data demonstrated that 90% of myopic eyes responded to MiSight® 1 day wear with a proportional treatment effect, meaning that younger and faster-progressing children receive the maximum benefit.2 Evidence also indicated a sustained slowing of eye growth over time.‡2Seven-year study evidence indicates that there is no rebound effect with MiSight® 1 day contact lenses §3,4 CooperVision also offers a range of orthokeratology designs and spectacles with Diffusion Optics Technology™ for myopia management.¶
# # #
U.S. Indications for Use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
China Indications for Use: MiSight® 1 day is indicated for the correction of myopia for patients with non-diseased phakic eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 D to -4.00 D with ≤ 0.75 diopters of astigmatism. It has the dual focal design with alternative multiple rings, which allows part of the light passing through the optical zone to focus in front of the retina, forming myopic defocus with the expectation to slow the change of axial length of the patients. Fitting and evaluation of the product should be in medical institutions by ophthalmologists with an intermediate title or above and with regular monitoring. It must be used in strict accordance with the IFU requirements.
*Compared to a single vision 1-day lens over a 3-year period.
†90% of myopic eyes respond to MiSight® 1 day treatment; ages 11-15 at start of wear, n=90.
‡While eyes are still growing; children fit ages 8-12 and followed for 6-years. n=40
§On average, for children aged 8-15 at initiation of treatment, there was no indication that accumulated treatment effect gained following 3 or 6 years of MiSight® 1 day wear was lost during a 12-month cessation study. Instead, eye growth reverted to expected, age average myopic progression rates.
¶Spectacles with Diffusion Optics Technology are not approved for sale in the United States.
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 14,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com
Mike McDougall, APR, Fellow PRSA, FAAO
McDougall Communications for CooperVision
email@example.com or +1-585-545-1815
1 Chamberlain P, Peixoto-de-Matos SC, Logan NS, Ngo C, Jones D, Young G. A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control. Optom Vis Sci. 2019 Aug;96(8):556-567.
2 Chamberlain P et al. Long-Term Effect of Dual-Focus Contact Lenses on Myopia Progression in Children: A 6-year Multicenter Clinical Trial. Optom Vis Sci 2022 Mar 1;99(3):204-212.
3 Chamberlain P, Arumugam B, et al. Myopia Progression on Cessation of Dual-Focus Contact Lens Wear: MiSight 1 day 7-Year Findings. Optom Vis Sci 2021;98:E-abstract 210049
4 Hammond D, Arumugam B, et al. Myopia Control Treatment Gains are Retained after Termination of Dual-focus Contact Lens Wear with No Evidence of a Rebound Effect. Optom Vis Sci 2021;98:E-abstract 215130